Chronic viral hepatitis C: Management update

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 6, 2000, Pages 827-833

  Gutfreund, Klaus S ^a   Bain, Vincent G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ARTHRALGIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CHRONIC HEPATITIS; DRUG INDUCED DISEASE; DRUG MIXTURE; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MONOTHERAPY; PATIENT MONITORING; PSYCHOPATHY; RASH; REPRODUCTIVE TOXICITY; REVIEW; TERATOGENICITY; VIRUS GENE; VIRUS LOAD;

EID: 0034696554     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. 1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5S.
2. 2. Louie M, Low D, Feinman S, Mclaughlin B, Simor AE. Prevalence of bloodborne infective agents among people admitted to a Canadian hospital. CMAJ 1992;146:1331-4.
3. 3. Chaudary R, Mo T. Antibody to hepatitis C virus in risk groups in Canada. Can J Infect Dis 1992;3:27-9.
4. 4. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26:21S-8S.
5. 5. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated ant-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
6. 6. Colombo M. The natural history of hepatitis C. Baillieres Clin Gastroenterol 1996;10:275-88.
7. 7. Major ME, Feinstone S. Molecular virology of hepatitis C. Hepatology 1997; 25:1527-38.
8. 8. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
9. 9. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998;59:563-78.
10. 10. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30:376-82.
11. 11. Barrera JM, Bruguera M, Guadalupe-Ercilla M, Gil C, Celis R, Gil MP. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-41.
12. 12. Farci P, Alter HJ, Womg D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
13. 13. Hino K, Sainokami S, Shimoda K, Niwa H, Lino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 1994;39:19-27.
14. 14. Lok ASF, Chien D, Choo QI, Chan TM, Chiu EKW, Chen IKP. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients, Hepatology 1993;18(3):497-502.
15. 15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of Interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
16. 16. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
17. 17. National Institutes of Health Consensus Development Conference Panel Statement: the treatment of chronic viral Hepatitis C. Hepatology 1997;26:2S-10S.
18. 18. Shahi HM, Sarin SK. Prevention of first variceal bleed: an appraisal of current therapies. Am J Gastroenterol 1999;93:2348-58.
19. 19. Tong MJ, El-Rarra N, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
20. 20. Chiaramonte M, Stroffolini T, Vian AStazi MA, Floreani A, Lorenzoni U, Lobello S, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7.
21. 21. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carrieres of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22: 432-8.
22. 22. Bizollon T, Ducerf C, Trepo C, Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999;44:575-8.
23. 23. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group. Gastroenterology 1999;117:619-25.
24. 24. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-31.
25. 25. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
26. 26. Shev S, Dhillon A, Lindh M, Serleus Z, Wejstral R, Widell A, et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver 1997;17:215-23.
27. 27. Yoshihara H, Noda K, Kamada T. Interelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Recent Dev Alcohol 1998;14:457-69.
28. 28. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
29. 29. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O. The long-term pathological evaluation of chronic hepatitis C. Hepatology 1996;23:1334-40.
30. 30. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P. Slow progression rate of fibrosis in hepatitis C virus patients with persistantly normal alanine transaminase activity. Hepatology 1998;27:868-72.
31. 31. Alberti A, Pontisso P, Chemelo L, Fattovich G, Benvegnu L. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995;22:38-41.
32. 32. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
33. 33. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997;26:137S-42S.
34. 34. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997;26:101S-7S.
35. 35. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998;93:2445-51.
36. 36. Salmeron J, Ruiz-Extrema A, Torres C, Rodriguez-Ramos L, Lavin I, Quintero D, et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999;19:275-80.
37. 37. Pol S, Couzigou P, Abergel A, Larrey D, Tran A, Poupon R, et al. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J Hepatol 1999;31:1-7.
38. 38. Nevens F, Goubau P, Van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-9.
39. 39. Dimopoulou M, Fatoutis K, Basiliou K, Ketikoglou J, Karvountzis G. Interferon alfa2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of a pilot study. Gut 1993;34:104-5.
40. 40. Rebetton [product monograph]. Point Claire (QC): Schering Canada; 1999.
41. 41. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19:25-33.
42. 42. Younossi ZM, Perillo RP. The roles of amantadine, rimantadine, urodeoxycholic acid and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19:95-102.
43. 43. Prieto M, Olaso C, Verdu C, Cordoba C, Gisbert C, Rayon M, et al. Does the healthy hepatitis C virus carrier state really exist? Hepatology 1995;22:417.
44. 44. Shakil A, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibodies to hepatitis C virus: clinical, biochemical, virological, and histologic features. The Hepatitis C Study Group Ann Intern Med 1995;123:330-7.
45. 45. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997;26:133S-6S.
46. 46. Serfaty L, Chazouillierres O, Pawlotsky J, Andreani T, Pellet C, Poupon R. Interferon alpha therapy in patients with chronic hepatitis C and persistantly normal aminotransferase activity. Gastroenterology 1996;110:291-5.
47. 47. Orito E, Mizokami M, Suzuki K, Ohba KI, Ohno T, Mizuno M, et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 1997;12:58-61.
48. 48. Marcellin P, Boyer N, Gervais A. Martinot M, Pouteau M, Castelnau C, et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
49. 49. Shindo M, Di Bisceglie AHJ. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992;15:1013-6.
50. 50. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-7.
51. 51. Lai M, Kao J, Yang P. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;339:1493-9.
52. 52. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-6.
53. 53. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
54. 54. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
55. 55. Vial T, Descotes J. Clinical toxicity of interferons. Drug Saf 1994;10:115-50.
56. 56. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:122S-7S.
57. 57. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997;113:1647-53.
58. 58. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa-2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-5.
59. 59. Benvegnu L, Noventa F, Fattowich G, Pontisso P, Alberti: A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-9.
60. 60. Kowdley KV. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Gastroenterology 1999;117:738-9.
61. 61. Sherman M. Hepatocellular carcinoma. Gastroenterologist 1995;3:55-66.